Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent
Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT
How this was made
The 30-second read
Why it matters
The disclosed data could trigger a short‑term rally and longer‑term re‑rating by analysts.
Market read
First‑report 8‑K with material clinical data; likely to move the stock and influence sector sentiment.
What to watch
Cash burn increase and reliance on a single lead asset could limit upside if later trials falter.
Definium reports Q3 2026 net loss of $51.0 million, narrower than a year ago on a warrant fair-value gain and higher interest income, while operating expenses rose sharply and Phase 3 DT120 ODT data was positive
Clinical and regulatory progress was strong in the quarter, with positive Phase 3 topline results in GAD and a Breakthrough Therapy designation in MDD. Financially, the quarterly net loss narrowed only because of a non-operating warrant gain and higher interest income, while operating expenses rose about 58% in the quarter as printed (from $45,669 thousand to $72,279 thousand). The nine-month net loss widened to $(287,045) thousand from $(133,357) thousand.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, Q3 2026 (three months ended Sept 30)GAAP | $46.1M | – | increase of $15.1 million |
| General and administrative expenses, Q3 2026 (three months ended Sept 30)GAAP | $26.1M | – | increase of $11.4 million |
| Total operating expenses, Q3 2026 (three months ended Sept 30)GAAP | $72.28M | – | – |
| Loss from operations, Q3 2026 (three months ended Sept 30)GAAP | −$72.28M | – | – |
| Interest income, Q3 2026 (three months ended Sept 30)GAAP | $10.14M | – | – |
| Interest expense, Q3 2026 (three months ended Sept 30)GAAP | −$1.15M | – | – |
| Change in fair value of 2022 USD Financing Warrants, Q3 2026 (three months ended Sept 30)GAAP | $12.35M | – | – |
| Total other income/(expense), Q3 2026 (three months ended Sept 30)GAAP | $21.32M | – | – |
| Net loss, Q3 2026 (three months ended Sept 30)GAAP | $51M | – | – |
| Comprehensive loss, Q3 2026 (three months ended Sept 30)GAAP | −$52.21M | – | – |
| Net loss per common share, basic, Q3 2026 (three months ended Sept 30)GAAP | $(0.37) | – | – |
| Net loss per common share, diluted, Q3 2026 (three months ended Sept 30)GAAP | $(0.46) | – | – |
| Research and development expenses, nine months ended Sept 30, 2026GAAP | $136.3M | – | – |
| General and administrative expenses, nine months ended Sept 30, 2026GAAP | $70.29M | – | – |
| Total operating expenses, nine months ended Sept 30, 2026GAAP | $206.6M | – | – |
| Loss from operations, nine months ended Sept 30, 2026GAAP | −$206.6M | – | – |
| Interest income, nine months ended Sept 30, 2026GAAP | $17.18M | – | – |
| Interest expense, nine months ended Sept 30, 2026GAAP | −$3.63M | – | – |
| Change in fair value of 2022 USD Financing Warrants, nine months ended Sept 30, 2026GAAP | −$93.93M | – | – |
| Total other income/(expense), nine months ended Sept 30, 2026GAAP | −$80.47M | – | – |
| Net loss, nine months ended Sept 30, 2026GAAP | −$287.0M | – | – |
| Comprehensive loss, nine months ended Sept 30, 2026GAAP | −$289.0M | – | – |
| Net loss per common share, basic, nine months ended Sept 30, 2026GAAP | $(2.42) | – | – |
| Net loss per common share, diluted, nine months ended Sept 30, 2026GAAP | $(2.42) | – | – |
| Cash, cash equivalents and investments as of Sept 30, 2026other | approximately $1.05 billion | – | – |
Capital returns
- No share repurchases, dividends or other capital return programs are reported in the filing.
- Common shares issued and outstanding were 136,887,557 as of Sept 30, 2026, compared with 98,776,265 as of Dec 31, 2025, and additional paid-in capital rose to $1,838,580 thousand from $913,914 thousand. The filing does not describe the transactions behind this increase.
What drove it
- The company attributes the Q3 2026 R&D increase of $15.1 million primarily to an $8.8 million increase in personnel-related costs tied to expansion of the R&D organization, a $5.9 million increase in DT120 development program expenses, and a $0.6 million increase in preclinical and other program expenses, partially offset by a $0.2 million decrease in DT402 program expenses.
- The company attributes the Q3 2026 G&A increase of $11.4 million primarily to a $3.5 million increase in corporate and government affairs expenses, a $3.4 million increase in commercial-preparedness related expenses, a $3.3 million increase in personnel-related expenses as organizational capabilities expanded, a $0.7 million increase in legal and patent expenses, a $0.4 million increase in other administrative expenses, and a $0.1 million increase in stock-based compensation.
- The company states that the decrease in Q3 2026 net loss to $51.0 million from $67.3 million was primarily attributable to a gain from the change in fair value of the 2022 USD financing warrants and higher interest income, partially offset by increased operating expenses.
- Interest income rose to $10,139 thousand in Q3 2026 from $2,262 thousand in Q3 2025, as printed in the statement of operations.
Concerns
- Total operating expenses rose to $72,279 thousand in Q3 2026 from $45,669 thousand a year earlier, and to $206,576 thousand for the nine months from $118,731 thousand.
- The quarterly net loss narrowed mainly because of the warrant fair-value gain of $12,350 thousand, which is a non-operating item. Loss from operations was $(72,279) thousand in the quarter.
- For the nine months, the change in fair value of the 2022 USD Financing Warrants was $(93,927) thousand, compared with $(17,774) thousand a year earlier, and the nine-month net loss widened to $(287,045) thousand from $(133,357) thousand.
- The filing reports no revenue. Its results are entirely pre-commercial expense and non-operating items, so the earnings read depends on clinical and regulatory progress rather than on sales.
- Commercial-preparedness and corporate and government affairs spending increased in the quarter, and the company has not yet received approval for DT120 ODT in any indication.
What to watch
- Timing of the DT120 ODT NDA filing, which the company expects in the first half of 2027.
- Part A topline results from the Phase 3 Ascend study in MDD, which the company expects in 2027.
- Start of the Phase 3 Haven study in PTSD, planned for 2027 with approximately 200 participants.
- Next steps for DT402 in ASD, including a planned study of multiple dosing paradigms expected to begin in 2027.
- Quarterly operating expense trajectory, given the rise in R&D and G&A spending noted in the filing.
- The planned first Commercial Day in the first half of 2027.
- Movement in the 2022 USD Financing Warrants fair value, which drove the non-operating swings in both the quarter and the nine months.
Balance sheet and cash flow
- Cash and cash equivalents were $241,150 thousand as of Sept 30, 2026, compared with $257,837 thousand as of Dec 31, 2025.
- Short-term investments were $805,698 thousand as of Sept 30, 2026, compared with $153,756 thousand as of Dec 31, 2025.
- Cash, cash equivalents and investments were approximately $1.05 billion as of Sept 30, 2026, compared with $411.6 million as of Dec 31, 2025, as stated in the release text.
- Total assets were $1,074,283 thousand as of Sept 30, 2026, compared with $440,100 thousand as of Dec 31, 2025.
- 2022 USD Financing Warrants (current liability) were $21,328 thousand as of Sept 30, 2026, compared with $40,905 thousand as of Dec 31, 2025.
- Credit facility, long-term was $36,661 thousand as of Sept 30, 2026, compared with $40,579 thousand as of Dec 31, 2025.
- Total liabilities were $106,249 thousand as of Sept 30, 2026, compared with $107,773 thousand as of Dec 31, 2025.
- Total shareholders' equity was $968,034 thousand as of Sept 30, 2026, compared with $332,327 thousand as of Dec 31, 2025.
- The company states that its cash, cash equivalents and investments as of Sept 30, 2026 will be sufficient to fund operations into 2030, based on its current operating plan and anticipated milestones.
- The filing does not include a cash flow statement or operating and free cash flow figures.
Analysis
Definium's third quarter was dominated by clinical news. The company reported positive topline Phase 3 results from the Voyage study (214 participants, placebo-adjusted HAM-A improvement of 5.4 points, p<0.0001) and the Panorama study (245 participants, placebo-adjusted improvement of 5.1 points, p<0.0001) in generalized anxiety disorder. It also received FDA Breakthrough Therapy designation for DT120 ODT in major depressive disorder following positive Phase 3 Emerge results, and reported positive initial Phase 2a results for DT402 in five adults with autism spectrum disorder. The release states that the DT120 ODT NDA filing is on track for the first half of 2027.
The income statement shows a company in a build-out phase. Research and development expenses were $46.1 million in the quarter against $31.0 million a year earlier, and general and administrative expenses were $26.1 million against $14.7 million. Total operating expenses were $72,279 thousand against $45,669 thousand, and the nine-month figure rose to $206,576 thousand from $118,731 thousand. The company attributes the growth to personnel expansion, DT120 development spending and commercial-preparedness costs. The filing reports no revenue line.
The reported net loss of $51.0 million (GAAP) was narrower than the $67.3 million a year earlier. The company says this improvement was primarily attributable to a gain from the change in fair value of the 2022 USD financing warrants, which contributed $12,350 thousand in the quarter, and higher interest income of $10,139 thousand against $2,262 thousand. Loss from operations was $(72,279) thousand. The nine-month picture is weaker: the warrant fair-value change was $(93,927) thousand against $(17,774) thousand a year earlier, and the nine-month net loss was $(287,045) thousand against $(133,357) thousand. Diluted and basic loss per share were $(0.46) and $(0.37) for the quarter, and $(2.42) for the nine months on both bases.
On the balance sheet, cash, cash equivalents and investments were approximately $1.05 billion as of Sept 30, 2026, against $411.6 million at Dec 31, 2025. Short-term investments rose to $805,698 thousand from $153,756 thousand, and shareholders' equity rose to $968,034 thousand from $332,327 thousand. Common shares outstanding increased to 136,887,557 from 98,776,265, and the filing does not describe the transactions behind this change. The company says the current cash position is sufficient to fund operations into 2030. The filing contains no cash flow statement and no capital return activity.
The filing provides no guidance and no prior-period outlook to compare against. The main items for readers to follow are the timing of the NDA, the Ascend and Haven readouts, the trajectory of operating expenses and the non-operating warrant line that drives period-to-period net loss swings.
Management, verbatim
Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT.
Rob Barrow, Chief Executive Officer
With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization.
Rob Barrow, Chief Executive Officer
Not in the filing
stated, not guessed- No revenue or product sales line is reported in the filing.
- No segment or geographic breakdown is provided.
- No financial guidance or outlook for revenue, expenses or other metrics is provided, and no prior outlook was supplied for comparison.
- Operating cash flow, investing cash flow and free cash flow are not reported; the filing contains no cash flow statement.
- Percentage changes for operating expense, loss from operations and net loss lines are not printed.
- Prior-quarter (Q2 2026) comparative figures are not printed.
- Dates of the balance sheet comparison for cash, total assets and equity are Dec 31, 2025, not the prior-year quarter.
- No share repurchase, dividend or other capital return information is reported.
- No analyst consensus, price target or share-price reaction is contained in the documents.
- Explanation for the increase in common shares outstanding and additional paid-in capital is not provided.
- Cash, cash equivalents and investments as of Sept 30, 2026 is printed only as approximately $1.05 billion; the underlying exact figure is not printed.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Definium Therapeutics is a Nasdaq‑listed late‑stage biopharma focused on psychiatric disorders.
Ticker impact
Definium Therapeutics disclosed positive Phase 3 topline results for DT120 ODT in GAD and MDD, plus Breakthrough Therapy designation and $1.05 bn cash runway.
upward pressure as investors price in potential approval and market opportunity
Phase 3 success and FDA Breakthrough status are material catalysts for a late‑stage biotech; market typically reacts positively to such news.
Market effects
Strengthens the psychiatric‑neurology biotech sector, may lift peer valuations.
Positive for US biotech listings, limited broader market effect.
Highlights continued pipeline momentum in mental‑health therapeutics worldwide.
Counterpoint
Skeptics may question durability of Phase 3 results and timeline to NDA, suggesting caution.
Key entities
- companyDefinium Therapeutics, Inc.
Issuer of the disclosed trial results.
- executiveRob Barrow
CEO who commented on the data.
